Publications by authors named "E Rault"
Article Synopsis
- VEXAS syndrome, identified in 2020, is caused by mutations in the UBA1 gene and shows a variety of clinical and hematological features, making it challenging to distinguish from other inflammatory conditions. !* -
- This study collected a dataset of 9,514 images of polymorphonuclear cells (PMNs) and used a convolutional neural network (CNN) to automate the detection of specific dysplastic features unique to VEXAS, achieving a high level of accuracy (AUC of 0.85-0.97). !* -
- Results indicate that automated analysis can effectively support hematologists in identifying potential VEXAS cases, suggesting a screening score for UBA1 mutational
Article Synopsis
- A study was conducted to compare perinatal outcomes between immediate and deferred selective termination of discordant twin pregnancies with anomalies, considering the risk of pregnancy loss.
- The results showed that the deferred selective termination group had a 100% survival rate for the healthy co-twin, while the immediate group had a 93.8% survival rate (P<.01).
- Additionally, the rate of preterm birth was significantly lower in the deferred group (20.2%) compared to the immediate group (66.7%), indicating more favorable outcomes with delayed procedures.*
Hepatosplenic T-cell lymphoma displays an original oyster-shell cytological pattern and a genomic profile distinct from that of γδ T-cell large granular lymphocytic leukemia.
Anne Desmares Simon Bouzy Florian Thonier Julien Goustille Francisco Llamas-Gutierrez Emmanuelle Rault
Haematologica
June 2024
Purpose: We report the results of the French multicentric phase II study MIITOP (NCT00960739), which evaluated tandem infusions of I-metaiodobenzylguanidine (mIBG) and topotecan in children with relapsed/refractory metastatic neuroblastoma (NBL).
Methods: Patients received I-mIBG on day 1, with intravenous topotecan daily on days 1-5. A second activity of I-mIBG was given on day 21 to deliver a whole-body radiation dose of 4 Gy, combined with a second course of topotecan on days 21-25.